The drug has been persistently boosting Dr Reddy's U.S. sales since its launch in 2022.
Other generic drugmakers such as Cipla, Sun Pharma and Zydus Lifesciences have also benefitted from rising sales of their own copycat versions of Revlimid in the U.S.
According to Reuters report, Bristol Myers is facing pressure from generic competition for Revlimid, once its top-selling drug.
Meanwhile, generic drugmakers are grappling with pricing pressures amid intensifying competition.
"Price erosion trends are stable," Dr Reddy's CFO Parag Agarwal said, adding he does not see any structural impact or change in the market.
Dr Reddy's consolidated net profit for three months ended March 31 rose 36.5% from a year earlier to 13.10 billion rupees (about $157 million), beating analysts' average estimates of 12.42 billion rupees, per LSEG data.
The drugmaker's total revenue climbed 13% to 71.14 billion, in line with analysts' expectations, led by a 29% climb in the North American generics business, its biggest segment. Sales in Europe rose 5%.
The company said M V Narasimham, who is currently deputy CFO, will take over as the finance chief from Parag Agarwal, who will retire on July 31.
Rival Cipla will report its fourth-quarter results on Friday.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd